Yuan, J. et al. Novel applied sciences and rising biomarkers for personalised most cancers immunotherapy. J. Immunother. Most cancers 4, 3 (2016).
Connors, J. et al. Utilizing the ability of innate immunoprofiling to know vaccine design, an infection, and immunity. Hum. Vaccines Immunother. 19, 2267295 (2023).
Ogunniyi, A. O. et al. Profiling human antibody responses by built-in single-cell evaluation. Vaccine 32, 2866–2873 (2014).
Stork, E. M. et al. Antigen-specific Fab profiling achieves molecular-resolution evaluation of human autoantibody repertoires in rheumatoid arthritis. Nat. Commun. 15, 3114 (2024).
Lu, R. M. et al. Improvement of therapeutic antibodies for the remedy of illnesses. J. Biomed. Sci. 27, 1 (2020).
Deshaies, R. J. Multispecific medication herald a brand new period of biopharmaceutical innovation. Nature 580, 329–338 (2020).
Zhong, X., D’antona, A. M., Karagiannis, S. & White, A. Latest advances within the molecular design and purposes of multispecific biotherapeutics. Antibodies 10, 13 (2021).
Weiner, G. J. Constructing higher monoclonal antibody-based therapeutics. Nat. Rev. Most cancers 15, 361–370 (2015).
Gérard, A. et al. Excessive-throughput single-cell activity-based screening and sequencing of antibodies utilizing droplet microfluidics. Nat. Biotechnol. 38, 715–721 (2020).
Muruato, A. E. et al. A high-throughput neutralizing antibody assay for COVID-19 analysis and vaccine analysis. Nat. Commun. 11, 4059 (2020).
Tickle, S. et al. Excessive-throughput screening for top affinity antibodies. J. Lab. Autom. 14, 303–307 (2009).
Schofield, D. J. et al. Software of phage show to excessive throughput antibody technology and characterization. Genome Biol. 8, R254 (2007).
Carlson, E. D., Gan, R., Hodgman, C. E. & Jewett, M. C. Cell-free protein synthesis: purposes come of age. Biotechnol. Adv. 30, 1185–1194 (2012).
Cubillos-Ruiz, A. et al. Engineering residing therapeutics with artificial biology. Nat. Rev. Drug Discov. 20, 941–960 (2021).
Gu, Y. et al. Cell-free protein synthesis system for bioanalysis: advances in strategies and purposes. Tendencies Anal. Chem. 161, 117015 (2023).
Slomovic, S., Pardee, Ok. & Collins, J. J. Artificial biology units for in vitro and in vivo diagnostics. Proc. Natl Acad. Sci. USA 112, 14429–14435 (2015).
Murray, C. J. & Baliga, R. Cell-free translation of peptides and proteins:from excessive throughput screening to scientific manufacturing. Curr. Opin. Chem. Biol. 17, 420–426 (2013).
Ramm, F. et al. Mammalian cell-free protein expression promotes the practical characterization of the tripartite non-hemolytic enterotoxin from Bacillus cereus. Sci. Rep. 10, 2887 (2020).
Thoring, L. et al. Cell-free methods based mostly on CHO cell lysates: optimization methods, synthesis of “difficult-to-express” proteins and future views. PLoS ONE 11, e0163670 (2016).
Garenne, D., Bowden, S. & Noireaux, V. Cell-free expression and synthesis of viruses and bacteriophages: purposes to medication and nanotechnology. Curr. Opin. Syst. Biol. 28, 100373 (2021).
Sullivan, C. J. et al. A cell-free expression and purification course of for fast manufacturing of protein biologics. Biotechnol. J. 11, 238–248 (2016).
Pardee, Ok. et al. Fast, low-cost detection of Zika virus utilizing programmable biomolecular parts. Cell 165, 1255–1266 (2016).
Silverman, A. D., Akova, U., Alam, Ok. Ok., Jewett, M. C. & Lucks, J. B. Design and optimization of a cell-free atrazine biosensor. ACS Synth. Biol. 9, 671–677 (2020).
Wen, Ok. Y. et al. A cell-free biosensor for detecting quorum sensing molecules in P. aeruginosa-infected respiratory samples. ACS Synth. Biol. 6, 2293–2301 (2017).
Hunt, A. C. et al. A fast cell-free expression and screening platform for antibody discovery. Nat. Commun. 14, 3897 (2023).
Ojima-Kato, T., Nagai, S. & Nakano, H. Ecobody expertise: fast monoclonal antibody screening methodology from single B cells utilizing cell-free protein synthesis for antigen-binding fragment formation. Sci. Rep. 7, 13979 (2017).
Stech, M. & Kubick, S. Cell-free synthesis meets antibody manufacturing: a evaluate. Antibodies 4, 12–33 (2015).
Ramachandran, N. et al. Self-assembling protein microarrays. Science 305, 86–90 (2004).
Gerber, D., Maerkl, S. J. & Quake, S. R. An in vitro microfluidic strategy to producing protein-interaction networks. Nat. Strategies 6, 71–74 (2009).
Blackburn, M. C., Petrova, E., Correia, B. E. & Maerkl, S. J. Integrating gene synthesis and microfluidic protein evaluation for fast protein engineering. Nucleic Acids Res. 44, e68 (2015).
Markin, C. J. et al. Revealing enzyme practical structure by way of high-throughput microfluidic enzyme kinetics. Science 373, eabf8761 (2021).
Norouzi, M. et al. Cell-free dot blot: an ultra-low-cost and sensible immunoassay platform for detection of anti-SARS-CoV-2 antibodies in human and animal sera. Microbiol. Spectr. 11, e0245722 (2023).
Hufnagel, Ok. et al. In situ, cell-free protein expression on microarrays and their use for the detection of immune responses. Bio-protocol 9, e3152 (2019).
Goshima, N. et al. Human protein manufacturing unit for changing the transcriptome into an in vitro-expressed proteome. Nat. Strategies 5, 1011–1017 (2008).
Morishita, R. et al. CF-PA2Vtech: a cell-free human protein array expertise for antibody validation in opposition to human proteins. Sci. Rep. 9, 19349 (2019).
Levy, M., Falkovich, R., Daube, S. S. & Bar-Ziv, R. H. Autonomous synthesis and meeting of a ribosomal subunit on a chip. Sci. Adv. 6, eaaz6020 (2020).
Vonshak, O. et al. Programming multi-protein meeting by gene-brush patterns and two-dimensional compartment geometry. Nat. Nanotechnol. 15, 783–791 (2020).
Buxboim, A. et al. A single-step photolithographic interface for cell-free gene expression and energetic biochips. Small 3, 500–510 (2007).
Bracha, D. et al. Entropy-driven collective interactions in DNA brushes on a biochip. Proc. Natl Acad. Sci. USA 110, 4534–4538 (2013).
Förste, S. et al. Computational evaluation of protein synthesis, diffusion, and binding in compartmental biochips. Microb. Cell Truth. 22, 244 (2023).
Buxboim, A., Daube, S. S. & Bar-Ziv, R. Artificial gene brushes: a construction–perform relationship. Mol. Syst. Biol. 4, 181 (2008).
Caschera, F. & Noireaux, V. Synthesis of two.3 mg/ml of protein with an all Escherichia coli cell-free transcription–translation system. Biochimie 99, 162–168 (2014).
Zhang, S., Garcia-D’Angeli, A., Brennan, J. P. & Huo, Q. Predicting detection limits of enzyme-linked immunosorbent assay (ELISA) and bioanalytical strategies on the whole. Analyst 139, 439–445 (2013).
Seydoux, E. et al. Evaluation of a SARS-CoV-2-infected particular person reveals improvement of potent neutralizing antibodies with restricted somatic mutation. Immunity 53, 98–105.e5 (2020).
Ter Meulen, J. et al. Human monoclonal antibody mixture in opposition to SARS coronavirus: synergy and protection of escape mutants. PLoS Med. 3, 1071–1079 (2006).
Gong, Y., Qin, S. & Dai, L. The glycosylation in SARS-CoV-2 and its receptor ACE2. Sign Transduct. Goal. Ther. 6, 396 (2021).
Telenti, A., Hodcroft, E. B. & Robertson, D. L. The evolution and biology of SARS-CoV-2 variants. Chilly Spring Harb. Perspect. Med. 12, a041390 (2022).
Huang, M. et al. Atlas of at the moment obtainable human neutralizing antibodies in opposition to SARS-CoV-2 and escape. Immunity 55, 1501–1514 (2022).
Lee, C. H. et al. Potential CD8+ T cell cross-reactivity in opposition to SARS-CoV-2 conferred by different coronavirus strains. Entrance. Immunol. 11, 579480 (2020).
Wu, W., Cheng, Y., Zhou, H., Solar, C. & Zhang, S. The SARS-CoV-2 nucleocapsid protein: its function within the viral life cycle, construction and capabilities, and use as a possible goal within the improvement of vaccines and diagnostics. Virol. J. 20, 6 (2023).
Movsisyan, M. et al. Monitoring the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity inside 2 years after COVID-19 an infection. Sci. Rep. 14, 13417 (2024).
Kightlinger, W. et al. A cell-free biosynthesis platform for modular development of protein glycosylation pathways. Nat. Commun. 10, 5404 (2019).
Marani, M., Katul, G. G., Pan, W. Ok. & Parolari, A. J. Depth and frequency of maximum novel epidemics. Proc. Natl Acad. Sci. USA 118, e2105482118 (2021).
Hurlburt, N. Ok. et al. Structural foundation for potent neutralization of SARS-CoV-2 and function of antibody affinity maturation. Nat. Commun. 11, 5413 (2020).
Gibson, D. G. et al. Enzymatic meeting of DNA molecules as much as a number of hundred kilobases. Nat. Strategies 6, 343–345 (2009).
Buxboim, A., Daube, S. S. & Bar-Ziv, R. Ultradense artificial gene brushes on a chip. Nano Lett. 9, 909–913 (2009).
Garamella, J., Marshall, R., Rustad, M. & Noireaux, V. The all E. coli TX-TL Toolbox 2.0: a platform for cell-free artificial biology. ACS Synth. Biol. 5, 344–355 (2016).
He, B. et al. Fast mutagenesis and purification of phage RNA polymerases. Protein Expr. Purif. 9, 142–151 (1997).
Yu, T., Laird, J. R., Prescher, J. A. & Thorpe, C. Gaussia princeps luciferase: a bioluminescent substrate for oxidative protein folding. Protein Sci. 27, 1509–1517 (2018).
Dupin, A. Cell-free immuno-profiling on a genetically programmed biochip. Zenodo https://doi.org/10.5281/zenodo.17151196 (2025).
